Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
British Journal of Cancer|January 13, 2016
Phase I trial outcomes in older patients with advanced solid tumoursK H Khan, T A Yap, A Ring, et al.
British Journal of Cancer|October 27, 2012
Association of creatine kinase and skin toxicity in phase I trials of anticancer agentsV Moreno Garcia, P Thavasu, M Blanco Codesido, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 11, 2020
Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotypeC Lu, A Terbuch, D Dolling, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2018
Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC countsD Lorente, D Olmos, J Mateo, et al.
British Journal of Cancer|May 29, 2008
Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancerN M G M Appels, M J Bolijn, K Chan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 16, 2012
Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapyC N Sternberg, A Molina, S North, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2009
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)L R Molife, G Attard, P C Fong, et al.
Gene Therapy|March 8, 2008
Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trialC L White, K R Twigger, L Vidal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 10, 2011
Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapyJ S de Bono, L R Molife, G Sonpavde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2004
Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunityJ S de Bono, S Y Rha, J Stephenson, et al.
Pageof 8